CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Authors
B. Godman Hill, A. Simoens, S. Selke, G. Selke Krulichová, I. Zampirolli Dias, C. Martin, A.P. Oortwijn, W. Timoney, A. Gustafsson, L.L. Voncina, L. Kwon, H.-Y. Gulbinovic, J. Gotham, D. Wale, J. Cristina Da Silva, W. Bochenek, T. Allocati, E. Kurdi, A. Ogunleye, O.O. Meyer, J.C. Hoxha, I. Malaj, A. Hierländer, C. Sauermann, R. Hamelinck, W. Petrova, G. Laius, O. Langner, I. Yfantopoulos, J. Joppi, R. Jakupi, A. Greiciute-Kuprijanov, I. Vella Bonanno, P. Piepenbrink, J. de Valk, V. Wladysiuk, M. Marković-Peković, V. Mardare, I. Fürst, J. Tomek, D. Obach Cortadellas, M. Zara, C. Pontes, C. McTaggart, S. Laba, T.-L. Melien, Ø. Wong-Rieger, D. Bae, S. Hill, R.
Publication date
1 January 2021
Publisher
Abstract
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3103202
Last time updated on 10/02/2023